Post hoc analyses reveal promising results from the LixiLan‐G trial involving adults with type 2 diabetes. Kudos to Dr. Frias, our NRI team, and everyone involved!

https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14068